Results 201 to 210 of about 457,293 (369)
ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers +7 more
wiley +1 more source
This letter reports our characterization of the transient motion of cells under an optically induced dielectrophoresis (ODEP) force field. Different types of human cells repeatably undergo a first-order transient motion response when subjected to a ...
Liang WF(梁文峰) +6 more
core
How Angular Mismatch and Surface Topography in Modular Head-Stem Taper Junctions in Total Hip Replacements Affects Fretting-Corrosion and Motion Under Uni-Axial Loading. [PDF]
Wade A +6 more
europepmc +1 more source
Velocity Response Analysis of the SCR Rigid Body Swing under Wave and Z-direction Motion
Bo Zhu +3 more
openalex +1 more source
ABSTRACT Background Cognitive impairment is a common non‐motor symptom in Multiple Sclerosis (MS), negatively affecting autonomy and Quality of Life (QoL). Innovative rehabilitation strategies, such as semi‐immersive virtual reality (VR) and computerized cognitive training (CCT), may offer advantages over traditional cognitive rehabilitation (TCR ...
Maria Grazia Maggio +8 more
wiley +1 more source
Bio-Inspired Motion-Contour-Guided Visual System for Contrast-Independent Looming Perception. [PDF]
Yao J, Zhang J, Zhong Z, He H, Wang H.
europepmc +1 more source
Is the manual following response an attempt to compensate for inferred self-motion? [PDF]
Yajie Zhang +4 more
openalex +1 more source
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source

